Contact Robbins LLP for Information About Leading the Treace Medical Concepts, Inc. Class Action Lawsuit
SAN DIEGO, April 23, 2025 /PRNewswire/ — Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Treace Medical Concepts, Inc. (NASDAQ: TMCI) securities between May 8, 2023 and May 7, 2024. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations that Treace Medical Concepts, Inc. (TMCI) Misled Investors Regarding Demand for its Primary Product
According to the complaint, during the class period, defendants failed to disclose that (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System, and (2) as a result, Treace Medical's revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function). Plaintiff alleges that when the truth was revealed, the price of Treace Medical's stock fell nearly 63%, to close at $4.17 per share on May 8, 2024.
What Now: You may be eligible to participate in the class action against Treace Medical Concepts, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 10, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against Treace Medical Concepts, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Applied Medical Technology, Inc. Unveils Redesigned Mobile App Aligned with Recent Website Refresh
BRECKSVILLE, Ohio., June 10, 2025 /PRNewswire/ — Applied Medical Technology, Inc. (AMT), a leader in innovative medical devices, is proud to announce the launch of its redesigned mobile application, AMT ONE Source®. This strategic update follows a successful website redesign completed late 2024, ensuring that both platforms now offer a cohesive, user-friendly digital experience. Enhancing User Experience Across PlatformsThe redesigned mobile app mirrors the modern, intuitive design language introduced during the website refresh. With a renewed focus on user experience and engagement, the mobile platform now features streamlined interfaces and updated information. 'In today's fast-paced healthcare environment, it is essential that our digital platforms are not only reliable but also easy to navigate and visually appealing,' said Bill Bentley, National Sales Manager. 'Created with our youngest patients in mind, the redesign was thoughtfully developed to be more engaging, age-appropriate, and easy to navigate—helping children and their families feel more supported and empowered throughout their healthcare journey.' Key Features and Benefits Unified Design Aesthetic: The mobile app adopts the clean, modern design previously launched on the website, providing a consistent look and feel across all digital touchpoints. Richer Content Experience: The app now features an expanded content database, providing a broader range of resources and information to support users with timely, relevant, and easy-to-access content. Improved Performance: The redesigned app features enhanced performance, with a new backend architecture that allows for faster content updates, easier maintenance, and more frequent improvements to keep the experience fresh and relevant. AMT partnered with Cleveland-Ohio based software company, Stream 9, on the redesign. Their strong track record in software design and development brought deep technical expertise and a strategic approach. 'We're fortunate in our business to develop custom software projects for businesses of all kinds; but it's especially rewarding to work on a project that will deliver such a direct benefit to patients and their caregivers. AMT brought a clear vision to the table, and we worked closely together to translate that into a modern, scalable, and user-friendly digital experience,' shared Kirk Miesle, Founder of Stream 9. The AMT ONE Source® app is available now on the App Store and Google Play. About AMT: Applied Medical Technology, Inc. (AMT) is a global leader in enteral and surgical devices committed to improving lives through innovation. For 40 years, AMT has bridged the gap between medical technology and patient needs, collaborating with healthcare professionals and users to develop high-quality, life-enhancing solutions. Our holistic approach prioritizes the well-being of the whole person, not just the device they use.
Malaysian Reserve
18 hours ago
- Malaysian Reserve
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
SAN DIEGO, June 9, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. 'Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change,' said Matt Abernethy, Chief Financial Officer, Neurocrine Biosciences. 'As we launch CRENESSITY, grow INGREZZA, and advance our pipeline, he joins Neurocrine at an exciting time when advancements in technology will play a critical role in advancing our mission to help more patients.' 'I am excited to join Neurocrine at such a pivotal time for the company,' Choi said. 'I look forward to leveraging innovative IT and digital solutions to strengthen the business and support the teams who work tirelessly to discover, develop and deliver critical treatments for patients.' Choi joins Neurocrine after a 13-year career at Thermo Fisher Scientific, most recently as the Vice President of AI Automation & Data. Previously, he was Global Vice President of Digital Platforms, Engineering & Generative AI; Vice President of Digital Solutions for APAC and Emerging Markets; and Vice President of Corporate Solutions & Integrations. Prior to that, he held IT roles at Life Technologies (prior to its acquisition by Thermo Fisher Scientific), SysGroup Inc., Serene Corporation, ADP, and Corio, Inc. and earned a Bachelor of Arts degree at the University of California, Berkeley. About Neurocrine Biosciences Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit and follow the company on LinkedIn, X, and Facebook. (*in collaboration with AbbVie) NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE, INGREZZA, and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc. © 2025 Neurocrine Biosciences, Inc. All Rights Reserved. 06/2025
The Sun
a day ago
- The Sun
Arlo Announces New Audio AI Smart Home Security Feature In Upgrade To Secure Plus Service Plan
SINGAPORE - Media OutReach Newswire - 10 June 2025 - Arlo Technologies, Inc. (NYSE: ARLO), a leading smart home security brand, has just announced the next evolution of Arlo's industry-leading home security subscription service in Australia & New Zealand featuring groundbreaking AI technology, Advanced Audio Detection. 'Arlo continues to push the boundaries of what's possible in home security with our relentless focus on industry-first innovations,' said Matthew McRae, Chief Executive Officer at Arlo. 'Leveraging Arlo Intelligence, a high-performance smart security AI engine with robust detection and recognition capabilities, Arlo Secure delivers a smarter, more personalised security experience that empowers quick and informed decision making.' Arlo Secure Plus enhances the features of Arlo devices and completes the security experience to provide consumers with total protection. Powered by Arlo Intelligence, Arlo Secure provides an intuitive, informed security experience with real, tangible value to users. Its comprehensive suite of AI features help users better understand what's happening in and around their homes, allowing for quick and appropriate responses to potential emergency events. Arlo Secure Plus has now expanded on the previously introduced Person Recognition, Vehicle Recognition, and Custom Detection capabilities to add Advanced Audio Detection. This new capability notifies users when critical sounds such as screams, gunshots, dog barks, glass breaking, or Smoke/CO alarms are detected. Each alert is designed to provide real-time awareness and enable swift action, further strengthening Arlo's commitment to proactive, intelligent security. Advanced Audio Detection includes: • Scream Detection: When your camera hears a scream, you'll get an alert so you can act quickly if needed. • Gunshot Detection: At the sound of gunfire, receive an alert about serious activity and view live video • Dog Bark Detection: When your dog barks, you'll be notified so you can view live video and determine if it's reacting to a threat or the next door neighbour's cat. • Glass Break Detection: Get an alert when your camera hears glass breaking and view live video, check your house or car, and notify family at home of suspicious activity. Across Australia and New Zealand, Advanced Audio Detection will be supported on the Essential Indoor 2K & Wired Floodlight and available to customers starting this month. A 30-day trial of Arlo Secure Plus is included with the purchase of these and other Arlo products. For more information on the full range of Arlo smart home security products and comprehensive list of features and services, visit
